185 related articles for article (PubMed ID: 27284449)
1. Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
Nukaga S; Naoki K; Kamo T; Masuzawa K; Yasuda H; Soejima K; Betsuyaku T
Mol Clin Oncol; 2016 Jun; 4(6):1085-1087. PubMed ID: 27284449
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
Chino H; Sekine A; Kitamura H; Kato T; Ogura T
Lung Cancer; 2015 Dec; 90(3):610-3. PubMed ID: 26452431
[TBL] [Abstract][Full Text] [Related]
3. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract][Full Text] [Related]
4. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with crizotinib after alectinib-induced interstitial lung disease.
Zhu N; Lin S; He L; Wang L; Kong W; Cao C
SAGE Open Med Case Rep; 2021; 9():2050313X211042991. PubMed ID: 34484794
[TBL] [Abstract][Full Text] [Related]
6. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
Kaira K; Naruse I; Shimizu K; Asao T
J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
[TBL] [Abstract][Full Text] [Related]
7. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
Nitawaki T; Sakata Y; Kawamura K; Ichikado K
BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
[TBL] [Abstract][Full Text] [Related]
8. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with
Myall NJ; Lei AQ; Wakelee HA
Transl Lung Cancer Res; 2021 Jan; 10(1):487-495. PubMed ID: 33569330
[TBL] [Abstract][Full Text] [Related]
9. Successful alectinib treatment after crizotinib-induced interstitial lung disease.
Fujiuchi S; Fujita Y; Sasaki T; Ohsaki Y
Respirol Case Rep; 2016 May; 4(3):e00156. PubMed ID: 27516885
[TBL] [Abstract][Full Text] [Related]
10. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy.
Ryu WK; Cha H; Park MH; Kim JS; Choi JS; Kim L; Lee KH; Nam HS
Front Oncol; 2022; 12():900966. PubMed ID: 36330497
[TBL] [Abstract][Full Text] [Related]
12. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
13. Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report.
Watanabe H; Tamura T; Shiozawa T; Ohara G; Kagohashi K; Kawaguchi M; Kurishima K; Satoh H; Hizawa N
Mol Clin Oncol; 2015 Jul; 3(4):889-891. PubMed ID: 26171201
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.
Créquit P; Wislez M; Fleury Feith J; Rozensztajn N; Jabot L; Friard S; Lavole A; Gounant V; Fillon J; Antoine M; Cadranel J
J Thorac Oncol; 2015 Aug; 10(8):1148-55. PubMed ID: 26200268
[TBL] [Abstract][Full Text] [Related]
16. Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy.
Maka VV; Krishnaswamy UM; Anil Kumar N; Chitrapur R; Kilara N
Oxf Med Case Reports; 2014 Apr; 2014(1):11-2. PubMed ID: 25988009
[TBL] [Abstract][Full Text] [Related]
17. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
18. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
20. Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.
Gemma A; Kusumoto M; Kurihara Y; Masuda N; Banno S; Endo Y; Houzawa H; Ueno N; Ohki E; Yoshimura A
J Thorac Oncol; 2019 Apr; 14(4):672-682. PubMed ID: 30521972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]